Generated by AI
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing immune-oncology technologies for hard-to-treat cancers. The company’s current work centers on its DNase platform, which is designed to target neutrophil extracellular traps (NETs) and support the effectiveness of existing cancer treatments such as immunotherapies. Xenetic Biosciences is also advancing product candidates including XBIO-015 and XBIO-020 for pancreatic carcinoma and other solid tumors, along with platform technologies such as PolyXen and XCart. In addition to oncology, the company has programs that address related therapeutic areas, including anemia in chronic kidney disease through ErepoXen. Headquartered in Framingham, Massachusetts, Xenetic Biosciences serves as a specialized biotechnology player with a pipeline oriented toward novel treatment approaches across oncology and selected adjacent indications.
Website945 Concord Street
Framingham, MA, 01701
United States
The latest articles about XBIO.
"This is a defining period for Xenetic as we work toward completing a transaction that we believe has the potential to fundamentally transform the Company's clinical development profile and long-term value proposition," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic Biosciences. "Santersus is expected to bring an established clinical-stage platform, two FDA Breakthrough Device Designations and a pipeline targeting serious diseases with substantial unme
Summary of Oct 28's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about XBIO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.